T-Cell Leukemia - Pipeline Review, H2 2015

Date: September 16, 2015
Pages: 91
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TFE6E9D236AEN
Leaflet:

Download PDF Leaflet

T-Cell Leukemia - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘T-Cell Leukemia - Pipeline Review, H2 2015’, provides an overview of the T-Cell Leukemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for T-Cell Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding T-Cell Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
T-Cell Leukemia Overview
Therapeutics Development
Pipeline Products for T-Cell Leukemia - Overview
Pipeline Products for T-Cell Leukemia - Comparative Analysis
T-Cell Leukemia - Therapeutics under Development by Companies
T-Cell Leukemia - Therapeutics under Investigation by Universities/Institutes
T-Cell Leukemia - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
T-Cell Leukemia - Products under Development by Companies
T-Cell Leukemia - Products under Investigation by Universities/Institutes
T-Cell Leukemia - Companies Involved in Therapeutics Development
Applied Immune Technologies Ltd
Astellas Pharma Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Chipscreen Biosciences Ltd
iDD biotech SAS
Kyowa Hakko Kirin Co., Ltd.
MediGene AG
Sanofi
Stemline Therapeutics, Inc.
Theravectys SA
T-Cell Leukemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AGS-67E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alemtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-906024 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target CD38 for cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CS-055 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDD-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INA-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-1AD3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMIG-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mogamulizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THV-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-Cell Leukemia - Recent Pipeline Updates
T-Cell Leukemia - Dormant Projects
T-Cell Leukemia - Discontinued Products
T-Cell Leukemia - Product Development Milestones
Featured News & Press Releases
Mar 23, 2015: THERAVECTYS Granted Authorization by the French National Agency for Medicines to Produce Lentiviral Vectors for Clinical Use and CAR-T Cell Therapies under GMP Standards
Feb 04, 2015: THERAVECTYS Obtains Orphan Drug Designation from the European Medicines Agency for Its Lentiviral Vector-Based Therapeutic Vaccine against Adult T-Cell Leukemia and Lymphoma
Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab
Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe
Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan
Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity
Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for T-Cell Leukemia, H2 2015
Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
T-Cell Leukemia - Pipeline by Applied Immune Technologies Ltd, H2 2015
T-Cell Leukemia - Pipeline by Astellas Pharma Inc., H2 2015
T-Cell Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2015
T-Cell Leukemia - Pipeline by Celgene Corporation, H2 2015
T-Cell Leukemia - Pipeline by Chipscreen Biosciences Ltd, H2 2015
T-Cell Leukemia - Pipeline by iDD biotech SAS, H2 2015
T-Cell Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
T-Cell Leukemia - Pipeline by MediGene AG, H2 2015
T-Cell Leukemia - Pipeline by Sanofi, H2 2015
T-Cell Leukemia - Pipeline by Stemline Therapeutics, Inc., H2 2015
T-Cell Leukemia - Pipeline by Theravectys SA, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
T-Cell Leukemia Therapeutics - Recent Pipeline Updates, H2 2015
T-Cell Leukemia - Dormant Projects, H2 2015
T-Cell Leukemia - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for T-Cell Leukemia, H2 2015
Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Applied Immune Technologies Ltd
Astellas Pharma Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Chipscreen Biosciences Ltd
iDD biotech SAS
Kyowa Hakko Kirin Co., Ltd.
MediGene AG
Sanofi
Stemline Therapeutics, Inc.
Theravectys SA
Skip to top


Ask Your Question

T-Cell Leukemia - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: